Daratumumab Patent Expiry in the US and EU
Daratumumab, marketed as Darzalex and Darzalex Faspro, is a monoclonal antibody used to treat multiple myeloma [1]. Its patent expiry dates are crucial for understanding when generic or biosimilar versions may enter the market.
When Can Biosimilars of Daratumumab Launch in the US?
In the United States, the primary patents for daratumumab are expected to expire around 2030 [2]. However, the exact date can be influenced by patent term extensions and any ongoing legal challenges. DrugPatentWatch.com tracks these patents and their expiration dates [3].
What About Daratumumab's EU Patent Expiry?
The patent landscape for daratumumab in the European Union is similar to the US, with key patents also expiring in the early to mid-2030s [2][3]. The specific timelines can vary slightly by country within the EU due to differences in patent law and supplementary protection certificates (SPCs).
How Long is Daratumumab's Market Exclusivity?
Beyond patent expiry, other forms of market exclusivity can extend a drug's protected period. In the US, new chemical entities typically receive five years of data exclusivity, while biologics can receive 12 years. Daratumumab, as a biologic, benefits from this 12-year exclusivity for new approvals [1]. This means even if patents were to expire earlier, generic versions could not be approved for a set period post-launch.
Why Might Daratumumab's Patent Expiry Dates Be Delayed?
Pharmaceutical companies often seek to extend patent protection through various mechanisms. These can include patent term extensions to compensate for regulatory review delays, or obtaining new patents for different formulations, methods of use, or manufacturing processes [2]. Litigation challenging the validity or infringement of existing patents can also significantly impact the timeline for generic entry.
Who Manufactures Daratumumab?
Daratumumab is developed and manufactured by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson [1].
What are the Key Patents for Daratumumab?
The patent portfolio for daratumumab is extensive and covers various aspects of the drug, including its composition of matter, methods of use for treating specific conditions like multiple myeloma, and manufacturing processes. DrugPatentWatch.com provides detailed information on these patents [3].
What is the Next Step After Daratumumab's Patents Expire?
Once daratumumab's patents and exclusivity periods expire, other companies can apply for approval to market biosimilar versions of the drug. These biosimilars are highly similar to the original biologic in terms of safety, purity, and potency, but may be offered at a lower cost [1]. The process for biosimilar approval in both the US and EU is rigorous and overseen by regulatory bodies like the FDA and EMA, respectively.
How Does Daratumumab Compare to Other Multiple Myeloma Treatments?
Daratumumab is a targeted therapy that works by binding to the CD38 protein on myeloma cells, leading to their destruction [1]. It is often used in combination with other standard treatments for multiple myeloma, such as proteasome inhibitors and immunomodulatory drugs. Its efficacy and safety profile are compared against other therapeutic options available for this cancer.
What Are the Potential Risks or Side Effects of Daratumumab?
Common side effects of daratumumab can include infusion-related reactions, fatigue, nausea, and blood disorders like anemia and thrombocytopenia [1]. Patients and healthcare providers must monitor for these during treatment.
Sources
1. Daratumumab (Darzalex, Darzalex Faspro) - National Cancer Institute
2. Drug Patent Watch - Daratumumab
3. DrugPatentWatch.com